Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of the patients develop irAEs within five months of treatment, and 11% develop severe irAEs requiring interventions. A predictive test for irAEs would be a crucial tool for monitoring for complications during and after ICI therapy. We performed an extensive review of potential predictive biomarkers for irAEs in patients who received ICI therapy. Currently, only thyroid-stimulating hormone is utilized in common clinical practice. This is due to the unavailability of commercial tests and unclear predictive values from various studies. Given the lack of single strong predictive biomarkers, some novel approaches using composite scores using genomic, transcriptomics, cytokine levels, or clinical parameters appear appealing. Still, these have yet to be validated and incorporated into clinical practice. Further research conducted to validate the models before implementing them into real-world settings will be of the utmost importance for irAE prediction.
免疫相关不良事件（irAEs）是免疫检查点抑制剂（ICI）治疗中最常见的并发症。随着ICI在实体瘤患者中的广泛应用，高达40%的患者在治疗五个月内出现irAEs，其中11%的患者出现需要干预的严重irAEs。对irAEs的预测性检测将成为监测ICI治疗期间及治疗后并发症的关键工具。我们对接受ICI治疗患者中潜在的irAEs预测生物标志物进行了广泛综述。目前，临床实践中仅常规使用促甲状腺激素作为预测指标，这主要是由于缺乏商业化的检测方法，且各项研究的预测价值尚不明确。鉴于缺乏单一强效的预测生物标志物，一些利用基因组学、转录组学、细胞因子水平或临床参数构建复合评分的新型方法显示出潜力，但这些方法仍需进一步验证并整合到临床实践中。在将这些模型应用于真实世界之前，开展进一步研究以验证其有效性，对于irAEs的预测至关重要。
肿瘤(癌症)患者之家